BeiGene Grants 42,648 ADS Restricted Share Units to 381 Employees, Equal to 0.04% of Total Share Capital

Bulletin Express06-05

BeiGene (BeOne Medicines Ltd.) announced that its Board compensation committee approved the issuance of 42,648 restricted share units (RSUs) on 1 June 2026 under the Fourth Amended and Restated 2016 Share Option and Incentive Plan.

The new award covers 381 employees and corresponds to 554,424 ordinary shares, representing approximately 0.04% of the company’s issued share capital on the grant date. Each RSU relates to one American Depositary Share (ADS), with every ADS equal to 13 ordinary shares.

Based on the closing price of US$279.68 per ADS on the grant date, the total notional value of the grant is about US$11.93 million (approximately HK$93.60 million).

Vesting Terms • 25% of the RSUs vest on each anniversary of the last trading day of the month following the employee’s start date over four years, subject to continued employment. • For 195 non-senior-manager grantees, 25% vests annually on 29 May from 2026 to 2029, also contingent on continued employment. • Certain awards may vest earlier in the event of termination or a change of control.

There are no performance conditions or claw-back provisions attached to these awards. The compensation committee considers the structure market-competitive and consistent with the plan’s objectives.

Following this grant, 61.08 million ordinary shares remain available for future awards under the 2016 Share Option and Incentive Plan.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1193936326?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-05 17:46","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1193936326","market":"hk","top_or_hot":-1,"title":"BeiGene Grants 42,648 ADS Restricted Share Units to 381 Employees, Equal to 0.04% of Total Share Capital","media":"Bulletin Express","content":"<p>BeiGene (BeOne Medicines Ltd.) announced that its Board compensation committee approved the issuance of 42,648 restricted share units (RSUs) on 1 June 2026 under the Fourth Amended and Restated 2016 Share Option and Incentive Plan.</p>\n<p>The new award covers 381 employees and corresponds to 554,424 ordinary shares, representing approximately 0.04% of the company’s issued share capital on the grant date. Each RSU relates to one American Depositary Share (ADS), with every ADS equal to 13 ordinary shares.</p>\n<p>Based on the closing price of US$279.68 per ADS on the grant date, the total notional value of the grant is about US$11.93 million (approximately HK$93.60 million).</p>\n<p>Vesting Terms  \n• 25% of the RSUs vest on each anniversary of the last trading day of the month following the employee’s start date over four years, subject to continued employment.  \n• For 195 non-senior-manager grantees, 25% vests annually on 29 May from 2026 to 2029, also contingent on continued employment.  \n• Certain awards may vest earlier in the event of termination or a change of control.</p>\n<p>There are no performance conditions or claw-back provisions attached to these awards. The compensation committee considers the structure market-competitive and consistent with the plan’s objectives.</p>\n<p>Following this grant, 61.08 million ordinary shares remain available for future awards under the 2016 Share Option and Incentive Plan.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BeiGene Grants 42,648 ADS Restricted Share Units to 381 Employees, Equal to 0.04% of Total Share Capital</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBeiGene Grants 42,648 ADS Restricted Share Units to 381 Employees, Equal to 0.04% of Total Share Capital\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-06-05 17:46</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>BeiGene (BeOne Medicines Ltd.) announced that its Board compensation committee approved the issuance of 42,648 restricted share units (RSUs) on 1 June 2026 under the Fourth Amended and Restated 2016 Share Option and Incentive Plan.</p>\n<p>The new award covers 381 employees and corresponds to 554,424 ordinary shares, representing approximately 0.04% of the company’s issued share capital on the grant date. Each RSU relates to one American Depositary Share (ADS), with every ADS equal to 13 ordinary shares.</p>\n<p>Based on the closing price of US$279.68 per ADS on the grant date, the total notional value of the grant is about US$11.93 million (approximately HK$93.60 million).</p>\n<p>Vesting Terms  \n• 25% of the RSUs vest on each anniversary of the last trading day of the month following the employee’s start date over four years, subject to continued employment.  \n• For 195 non-senior-manager grantees, 25% vests annually on 29 May from 2026 to 2029, also contingent on continued employment.  \n• Certain awards may vest earlier in the event of termination or a change of control.</p>\n<p>There are no performance conditions or claw-back provisions attached to these awards. The compensation committee considers the structure market-competitive and consistent with the plan’s objectives.</p>\n<p>Following this grant, 61.08 million ordinary shares remain available for future awards under the 2016 Share Option and Incentive Plan.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"06160","symbol_name":"百济神州","start_time":0,"source_url":"","article_id":"1193936326","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1193936326","pubTimestamp":1780652794,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"BeiGene (BeOne Medicines Ltd.) announced that its Board compensation committee approved the issuance of 42,648 restricted share units (RSUs) on 1 June 2026 under the Fourth Amended and Restated 2016...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"06160":"百济神州"},"translate_title":"百济神州向381名员工授予42,648份ADS限制性股票单位，相当于总股本的0.04%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"06160":1},"content_text":"BeiGene (BeOne Medicines Ltd.) announced that its Board compensation committee approved the issuance of 42,648 restricted share units (RSUs) on 1 June 2026 under the Fourth Amended and Restated 2016 Share Option and Incentive Plan.\nThe new award covers 381 employees and corresponds to 554,424 ordinary shares, representing approximately 0.04% of the company’s issued share capital on the grant date. Each RSU relates to one American Depositary Share (ADS), with every ADS equal to 13 ordinary shares.\nBased on the closing price of US$279.68 per ADS on the grant date, the total notional value of the grant is about US$11.93 million (approximately HK$93.60 million).\nVesting Terms  \n• 25% of the RSUs vest on each anniversary of the last trading day of the month following the employee’s start date over four years, subject to continued employment.  \n• For 195 non-senior-manager grantees, 25% vests annually on 29 May from 2026 to 2029, also contingent on continued employment.  \n• Certain awards may vest earlier in the event of termination or a change of control.\nThere are no performance conditions or claw-back provisions attached to these awards. The compensation committee considers the structure market-competitive and consistent with the plan’s objectives.\nFollowing this grant, 61.08 million ordinary shares remain available for future awards under the 2016 Share Option and Incentive Plan.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"SGX","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.44.0","shortVersion":"4.44.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1193936326","isCrawlerRequest":true}